Gene name UniProt ID NCBI ID EC# (optional) 1 2 3 4 5 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 Notes ACSL1 P33121 2180 6.2.1.3 P P AA remodeling; Long-chain-fatty-acid--CoA ligase 1; Activation of long-chain fatty acids for both synthesis of cellular lipids, and degradation via beta-oxidation. Preferentially uses palmitoleate, oleate and linoleate; MSL: activates fatty acids for extension by addition of CoA ACSL3 O95573 2181 6.2.1.3 I I AA remodeling ACSL4 O60488 2182 6.2.1.3 D D AA remodeling ACSL5 Q9ULC5 51703 6.2.1.3 P P AA remodeling ACSL6 Q9UKU0 23305 D PMID 10548543 demonstrates that it can form arachidonyl-CoA. SLC27A2 O14975 11001 6.2.1.- I I AA remodeling MBOAT7 Q96N66 79143 2.3.1.- D AA remodeling. Bob notes this is specific to AA. aka LPIAT. LPCAT1 Q8NF37 79888 2.3.1.- I AA remodeling LPCAT2 Q7L5N7 54947 2.3.1.- D AA remodeling LPCAT3 Q6P1A2 10162 2.3.1.- D AA remodeling. Bob notes this is specific to AA. aka MBOAT5. AGPAT2 O15120 10555 2.3.1.51 D AA remodeling AGPAT4 Q9NRZ5 56895 2.3.1.51 P AA remodeling AGPAT5 Q9NUQ2 55326 2.3.1.51 D AA remodeling LCAT P04180 3931 2.3.1.43 D Central enzyme in the extracellular metabolism of plasma lipoproteins. Synthesized mainly in the liver and secreted into plasma where it converts cholesterol and phosphatidylcholines (lecithins) to cholesteryl esters and lysophosphatidylcholines on the surface of high and low density lipoproteins (HDLs and LDLs). The cholesterol ester is then transported back to the liver. Has a preference for plasma 16:0-18:2 or 18:O-18:2 phosphatidylcholines. Also produced in the brain by primary astrocytes, and esterifies free cholesterol on nascent APOE-containing lipoproteins secreted from glia and influences cerebral spinal fluid (CSF) APOE- and APOA1 levels. Together with APOE and the cholesterol transporter ABCA1, plays a key role in the maturation of glial-derived, nascent lipoproteins. Required for remodeling high-density lipoprotein particles into their spherical forms. AWAT2 Q6E213 158835 2.3.1.75 I AA remodeling ACAD9 Q9H845 28976 1.3.99.- D AA remodeling;Has a dehydrogenase activity on palmitoyl-CoA (C16:0) and stearoyl-CoA (C18:0). It is three times more active on palmitoyl-CoA than on stearoyl-CoA. Has little activity on octanoyl-CoA (C8:0), butyryl-CoA (C4:0) or isovaleryl-CoA (5:0). SOAT1 P35610 6646 2.3.1.26 I AA remodeling; Catalyzes the formation of fatty acid-cholesterol esters. ACAT1 P24752 38 2.3.1.9 D AA remodeling; Acetyl-CoA acetyltransferase, mitochondrial; 2 acetyl-CoA = CoA + acetoacetyl-CoA. PAFAH2 Q99487 5051 3.1.1.47 I AA remodeling ACOT1 Q86TX2 641371 I In 16940157, had activity with 16:1, 18:1, 18:1 trans, but was not tested with other unsaturated fatty acids. ACOT2 P49753 10965 I In 16940157, had activity with 16:1, 18:1, 18:1 trans, but was not tested with other unsaturated fatty acids. ACOT4 Q8N9L9 122970 D Activity with 20:4 as substrate in 16940157. ACOT7 O00154 11332 I ACOT7 had very low activity with arachidonyl-CoA, but had greater activity with other long chain acyl-CoAs, including oleoyl-CoA (10578051) ACOT8 O14734 10005 P ACOT8 was ssayed with n-decanoyl-CoA in 10092594. Mouse ACOT8 showed activity with arachidonyl-CoA (11673457), A review article (22465940) suggests that based on broad substrate specificity of mouse and rat ACOT8 it is likely that human ACOT8 also has broad specificity, ACOT8 (AKA hTE) appears to prefer medium chain acyl-CoAs (9153233) with maximal activity for C14-CoA and no activity for C18- and C20-CoA, PMID 9299485 also shows preference for medium chain acyl-CoAs ACOT11 Q8WXI4 26027 P AKA BFIT and THEM1 (23700546), mouse Them1 can hydrolyze palmitoyl-CoA (22993230), human BFIT exhibited activity with butyryl- < lauroyl- < myristoyl- < palmitoyl-CoA (22897136) suggesting preference for longer chain substrates, not assayed with arachidonyl-CoA, or unsaturated substrates ACOT13 Q9NPJ3 55856 D In (19170545) enzyme had demonstrated activity with arachidonoyl-CoA BAAT Q14032 570 D In (12810727) enzyme demonstrated thioesterase activity and conjugation to glycine activity for 20:4. LIPA P38571 3988 3.1.1.13 I AA remodeling LIPE Q05469 3991 3.1.1.79 P AA remodeling LIPG Q9Y5X9 9388 3.1.1.3 D D AA remodeling; Has phospholipase and triglyceride lipase activities. Hydrolyzes high density lipoproteins (HDL) more efficiently than other lipoproteins. PLA2G1B P04054 5319 3.1.1.4 D PA2 catalyzes the calcium-dependent hydrolysis of the 2-acyl groups in 3-sn-phosphoglycerides. PLA2G2A P14555 5320 3.1.1.4 D Catalyzes the calcium-dependent hydrolysis of the 2-acyl groups in 3-sn-phosphoglycerides. PLA2G2D Q9UNK4 26279 3.1.1.4 D PA2 catalyzes the calcium-dependent hydrolysis of the 2-acyl groups in 3-sn-phosphoglycerides. L-alpha-1-palmitoyl-2-linoleoyl phosphatidylethanolamine is more efficiently hydrolyzed than the other phospholipids examined. PLA2G2E Q9NZK7 30814 3.1.1.4 D PA2 catalyzes the calcium-dependent hydrolysis of the 2-acyl groups in 3-sn-phosphoglycerides. Has a preference for arachidonic-containing phospholipids. PLA2G2F Q9BZM2 64600 3.1.1.4 D PA2 catalyzes the calcium-dependent hydrolysis of the 2-acyl groups in 3-sn-phosphoglycerides. Hydrolyzes phosphatidylglycerol versus phosphatidylcholine with a 15-fold preference. PLA2G3 Q9NZ20 50487 3.1.1.4 D PA2 catalyzes the calcium-dependent hydrolysis of the 2-acyl groups in 3-sn-phosphoglycerides. Shows an 11-fold preference for phosphatidylglycerol over phosphatidylcholine (PC). Preferential cleavage: 1-palmitoyl-2-linoleoyl-phosphatidylethanolamine (PE) > 1-palmitoyl-2-linoleoyl-PC > 1-palmitoyl-2-arachidonoyl-PC > 1-palmitoyl-2-arachidonoyl-PE. Plays a role in ciliogenesis. PLA2G4A P47712 5321 D Selectively hydrolyzes arachidonyl phospholipids in the sn-2 position releasing arachidonic acid. Together with its lysophospholipid activity, it is implicated in the initiation of the inflammatory response.; MSL: UniProt shows 3.1.1.4 and 3.1.1.5 domains, but not experimental links. PLA2G4B P0C869 100137049 3.1.1.4 D Calcium-dependent phospholipase A2 that selectively hydrolyzes glycerophospholipids in the sn-2 position with a preference for arachidonoyl phospholipids PLA2G4C Q9UP65 8605 3.1.1.4 D Phosphatidylcholine + H(2)O = 1-acylglycerophosphocholine + a carboxylate. PLA2G4D Q86XP0 283748 3.1.1.4 D Calcium-dependent phospholipase A2 that selectively hydrolyzes glycerophospholipids in the sn-2 position. Not arachidonic acid-specific but has linoleic acid-specific activity. PLA2G4E Q3MJ16 123745 3.1.1.4 P Calcium-dependent phospholipase A2 that selectively hydrolyzes glycerophospholipids in the sn-2 position (By similarity). PLA2G4F Q68DD2 255189 3.1.1.4 P Calcium-dependent phospholipase A2 that selectively hydrolyzes glycerophospholipids in the sn-2 position. Has higher enzyme activity for phosphatidylethanolamine than phosphatidylcholine (By similarity). PLA2G5 P39877 5322 3.1.1.4 D PA2 catalyzes the calcium-dependent hydrolysis of the 2-acyl groups in 3-sn-phosphoglycerides. PLA2G6 O60733 8398 3.1.1.4 D Catalyzes the release of fatty acids from phospholipids. It has been implicated in normal phospholipid remodeling, nitric oxide-induced or vasopressin-induced arachidonic acid release and in leukotriene and prostaglandin production. May participate in fas mediated apoptosis and in regulating transmembrane ion flux in glucose-stimulated B-cells. Has a role in cardiolipin (CL) deacylation. Required for both speed and directionality of monocyte MCP1/CCL2-induced chemotaxis through regulation of F-actin polymerization at the pseudopods. PLA2G10 O15496 8399 3.1.1.4 D PA2 catalyzes the calcium-dependent hydrolysis of the 2-acyl groups in 3-sn-phosphoglycerides. Has a powerful potency for releasing arachidonic acid from cell membrane phospholipids. Prefers phosphatidylethanolamine and phosphatidylcholine liposomes to those of phosphatidylserine. PLA2G12A Q9BZM1 81579 3.1.1.4 D PA2 catalyzes the calcium-dependent hydrolysis of the 2-acyl groups in 3-sn-phosphoglycerides. Does not exhibit detectable activity toward sn-2-arachidonoyl- or linoleoyl-phosphatidylcholine or -phosphatidylethanolamine. PLA2G12B Q9BX93 84647 3.1.1.4 (putative) P P AA remodeling; MSL: only evidence is indirect PLA2G16 P53816 11145 D When assayed with radioactive substrates with palmitoyl at the sn-1 position and arachidonoyl at the sn-2 position more PLA1 activity than PLA2 activity is observed (19615464). PLB1 Q6P1J6 151056 D Phosphatidylcholine + H(2)O = 1-acylglycerophosphocholine + a carboxylate. PNPLA2 Q96AD5 57104 D PMID 15364929 shows that the human protein is capable of releasing AA from a triacylglycerol in vitro ELOVL2 Q9NXB9 54898 2.3.1.199 D ELOVL5 Q9NYP7 60481 2.3.1.199 D FADS1 O60427 3992 1.14.19.- D FADS2 O95864 9415 1.14.19.- D PTGS1 P23219 5742 D COX1 PTGS2 P35354 5743 1.14.99.1 D COX2 PTGIS Q16647 5740 5.3.99.4 D Catalyzes the isomerization of prostaglandin H2 to prostacyclin (= prostaglandin I2). PTGIR P43119 5739 D Receptor for prostacyclin (prostaglandin I2 or PGI2) PTGDS P41222 5730 5.3.99.2 D Catalyzes the conversion of PGH2 to PGD2 HPGDS O60760 27306 5.3.99.2 D Bifunctional enzyme which catalyzes both the conversion of PGH2 to PGD2... PTGES O14684 9536 5.3.99.3 D Catalyzes the oxidoreduction of prostaglandin endoperoxide H2 (PGH2) to prostaglandin E2 (PGE2). PTGES2 Q9H7Z7 80142 5.3.99.3 D Isomerase that catalyzes the conversion of unstable intermediate of prostaglandin E2 H2 (PGH2) into the more stable prostaglandin E2 (PGE2) form. PTGES3 Q15185 10728 5.3.99.3 D Lipid metabolism; prostaglandin biosynthesis. AKR1B1 P15121 231 1.1.1.21 D MSL: assigned to prostaglandin synthesis based on Bob Murphy's Excel spreadsheet AKR1C3 P42330 8644 1.-.-.- D Catalyzes the reduction of prostaglandin (PG) D2, PGH2 and phenanthrenequinone (PQ) and the oxidation of 9-alpha,11-beta-PGF2 to PGD2. CBR1 P16152 873 1.1.1.184 D Can convert prostaglandin E2 to prostaglandin F2-alpha CBR3 O75828 874 1.1.1.184 P KEGG: hsa00590 --- Prostaglandins; Acts on a wide range of carbonyl compounds, including ... prostaglandins E and F, reducing them to the corresponding alcohol. FAM213B Q8TBF2 127281 1.11.1.20 P Catalyzes the reduction of prostaglandin-ethanolamide H(2) (prostamide H(2)) to prostamide F(2alpha) with NADPH as proton donor. Also able to reduce prostaglandin H(2) to prostaglandin F(2alpha) (By similarity). PTGDR Q13258 5729 D Receptor for prostaglandin D2 (PGD2) PTGDR2 Q9Y5Y4 11251 D Receptor for prostaglandin D2 (PGD2). Coupled to the G(i)-protein. PTGER1 P34995 5731 D Receptor for prostaglandin E2 (PGE2). PTGER2 P43116 5732 D Receptor for prostaglandin E2 (PGE2) PTGER3 P43115 5733 D Receptor for prostaglandin E2 (PGE2) PTGER4 P35408 5734 D Receptor for prostaglandin E2 (PGE2). PTGFR P43088 5737 D Receptor for prostaglandin F2-alpha (PGF2-alpha). TBXAS1 P24557 6916 5.3.99.5 D Thromboxanes TBXA2R P21731 6915 D Receptor for thromboxane A2 (TXA2), a potent stimulator of platelet aggregation. ALOX5 P09917 240 1.13.11.34 D Catalyzes the first step in leukotriene biosynthesis, and thereby plays a role in inflammatory processes. KEGG: hsa00590 --- 5-HETEs and Leukotrienes pathway, also lipoxins (but lipoxins mainly through ALOX15) MAPKAPK2 P49137 9261 2.7.11.1 D ALOX5AP P20292 241 D Required for leukotriene biosynthesis by ALOX5 (5-lipoxygenase). Anchors ALOX5 to the membrane. Binds arachidonic acid, and could play an essential role in the transfer of arachidonic acid to ALOX5. Binds to MK-886, a compound that blocks the biosynthesis of leukotrienes. GPX1 P07203 2876 1.11.1.9 D KEGG: hsa00590 --- ALOX5--->5-HETEs --- Leukotrienes GPX2 P18283 2877 1.11.1.9 I KEGG: hsa00590 --- ALOX5--->5-HETEs --- Leukotrienes GPX3 P22352 2878 1.11.1.9 D KEGG: hsa00590 --- ALOX5--->5-HETEs --- Leukotrienes GPX4 P36969 2879 1.11.1.12 D GPX5 O75715 2880 1.11.1.9 P KEGG: hsa00590 --- ALOX5--->5-HETEs --- Leukotrienes GPX6 P59796 257202 1.11.1.9 P KEGG: hsa00590 --- ALOX5--->5-HETEs --- Leukotrienes GPX7 Q96SL4 2882 1.11.1.9 P KEGG: hsa00590 --- ALOX5--->5-HETEs --- Leukotrienes LTA4H P09960 4048 3.3.2.6 D Epoxide hydrolase that catalyzes the final step in the biosynthesis of the proinflammatory mediator leukotriene B4. Has also aminopeptidase activity. LTC4S Q16873 4056 4.4.1.20 D D Catalyzes the conjugation of leukotriene A4 with reduced glutathione to form leukotriene C4. DPEP1 P16444 1800 3.4.13.19 D Converts leukotriene D4 to leukotriene E4; it may play an important role in the regulation of leukotriene activity. DPEP2 Q9H4A9 64174 3.4.13.19 D Probable metalloprotease which hydrolyzes leukotriene D4 (LTD4) into leukotriene E4 (LTE4) By similarity. GGT1 P19440 2678 2.3.2.2 D Leukotriene C(4) + H(2)O = leukotriene D(4) + L-glutamate. GGT5 P36269 2687 2.3.2.2 D Converts leukotriene C4 (LTC4) to leukotriene D4 (LTD4). GGT6 Q6P531 124975 2.3.2.2 P KEGG: hsa00590 --- Leukotrienes GGT7 Q9UJ14 2686 2.3.2.2 P KEGG: hsa00590 --- Leukotrienes MGST2 Q99735 4258 D See UniProt entry; catalyzes LTA4 --> LTC4 MGST3 O14880 4259 D PTGR1 Q14914 22949 1.3.1.- D CYSLTR1 Q9Y271 10800 D Receptor for cysteinyl leukotrienes mediating bronchoconstriction of individuals with and without asthma. CYSLTR2 Q9NS75 57105 D Receptor for cysteinyl leukotrienes. OXGR1 Q96P68 27199 P Official name is OXGR1. Only evidence for role as a leukotriene receptor is 1 paper in mouse (PMID 23504326, as of 092013) LTB4R Q15722 1241 D Is a receptor for leukotriene B4, a potent chemoattractant involved in inflammation and immune response. LTB4R2 Q9NPC1 56413 D Low-affinity receptor for leukotrienes including leukotriene B4. GPR17 Q13304 2840 I EC50 values for LTD4 and LTC4 on the order of nM when expressed in 1321N1 and COS-7 cells (16990797). However, 20148890 shows no activation or binding with by LTC4 and LTD4. ABCC1 P33527 4363 D ABCC4 O15439 10257 D HPGD P15428 3248 1.1.1.141 D ALOX15 P16050 246 1.13.11.33 D D Converts arachidonic acid to 15S-hydroperoxyeicosatetraenoic acid. Also acts on C-12 of arachidonate as well as on linoleic acid. KEGG: hsa00590 --- 15-HETEs and lipoxins ALOX15B O15296 247 1.13.11.33 D Converts arachidonic acid exclusively to 15S-hydroperoxyeicosatetraenoic acid, while linoleic acid is less well metabolized. KEGG: hsa00590 --- 15-HETEs and lipoxins ALOX12B O75342 242 1.13.11.- D Converts arachidonic acid to 12R-hydroperoxyeicosatetraenoic acid (12R-HPETE); ; KEGG: hsa00590 --- 12-HETEs ALOX12 P18054 239 1.13.11.31 D Oxygenase and 14,15-leukotriene A4 synthase activity; KEGG: hsa00590 --- 12-HETEs ALOXE3 Q9BYJ1 59344 1.13.11.- D We are informing UniProt that their curation stating that ALOXE3 is involvedin leukotriene synthesis is mistaken. CYP1A1 P04798 1543 1.14.14.1 D D D CYP1A2 P05177 1544 1.14.14.1 D D D PharmGKB: PA165816736 --- Celecoxib metabolism CYP1B1 Q16678 1545 1.14.14.1 D D D CYP2B6 P20813 1555 1.14.14.1 D D KEGG: hsa00590 --- EETs (see PMID:11451964) CYP2C8 P10632 1558 1.14.14.1 D D D KEGG: hsa00590 --- EETs --- 15-HETEs --- 16 HETEs CYP2C9 P11712 1559 1.14.14.1 D D D KEGG: hsa00590 --- EETs --- 15-HETEs --- 16 HETEs CYP2C18 P33260 1562 1.14.14.1 P D P KEGG: hsa00590 --- EETs --- 15-HETEs --- 16 HETEs CYP2C19 P33261 1557 1.14.14.1 D D D KEGG: hsa00590 --- EETs --- 15-HETEs --- 16 HETEs CYP2D6 P10635 1565 1.14.14.1 D PharmGKB: PA165816736 --- CYP2D6 is inhibited by celecoxib, but is not directly involved in arachidonic acid metabolism CYP2E1 P05181 1571 1.14.14.1 D D KEGG: hsa00590 --- 19 HETEs CYP2J2 P51589 1573 1.14.14.1 D D D KEGG: hsa00590 --- 19 HETEs --- 15-HETEs --- EETs CYP2U1 Q7Z449 113612 1.14.14.1 D D D KEGG: hsa00590 --- 19 HETEs CYP3A4 P08684 1576 1.14.13.- D PharmGKB: PA165816736 CYP4A11 Q02928 1579 1.14.15.3 D D D KEGG: hsa00590 --- 20-HETEs --- EETs CYP4A22 Q5TCH4 284541 1.14.15.3 P P P KEGG: hsa00590 --- 20-HETEs --- EETs CYP4F2 P78329 8529 1.14.13.30 D D D KEGG: hsa00590 --- 20-HETEs CYP4F3 Q08477 4051 1.14.13.30 D D D KEGG: hsa00590 --- 20-HETEs CYP4F8 P98187 11283 1.14.13.30 D D KEGG: hsa00590 --- 20-HETEs CYP4F11 Q9HBI6 57834 1.14.13.30 D D KEGG: hsa00590 --- 20-HETEs CYP4F22 Q6NT55 126410 1.14.13.30 D D KEGG: hsa00590 --- 20-HETEs EPHX2 P34913 2053 3.3.2.10 D KEGG: hsa00590 --- DHETs (epoxides)